Heng Mei, Ph.D&M.D
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
5
4
0
N/A
0
1
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
Analytics
Trial Phases
No phase data
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Stanislaw R. Burzynski, MD, PhD
Burzynski Research Institute
Shared therapeutic areas:
John D. Hainsworth, MD
SCRI Development Innovations, LLC
Shared therapeutic areas:
Mary Horowitz, MD
Center for International Blood and Marrow Transplant Research
Shared therapeutic areas:
Arnon Nagler, MD
Chaim Sheba Medical Center
Shared therapeutic areas:
Yves Beguin, MD, PhD
CHU-ULg
Shared therapeutic areas:
lei zhang, MD
Chinese Academy of Medical Science and Blood Disease Hospital
Shared therapeutic areas:
Thomas Ortel, MD
Duke University
Shared therapeutic areas:
Roberto Hernández Martín, MD
Hospital Virgen de la Concha
Shared therapeutic areas:
Elena Pérez Ceballos, MD
Hospital Morales Meseguer
Shared therapeutic areas:
Nigel Key, MD
University of North Carolina, Chapel Hill
Shared therapeutic areas:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Safety and Efficacy of PRG-1801 in Recurrent/Refractory Primary Immune Thrombocytopenia (ITP)
Ripertamab Plus Eltrombopag vs. Eltrombopag in ITP Patients Post-Steroid Failure
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia
All 5 trials loaded